BioCentury
ARTICLE | Company News

CytomX, Bristol-Myers deal

January 25, 2016 8:00 AM UTC

CytomX received a $10 million milestone payment from Bristol-Myers Squibb under a 2014 deal granting BMS exclusive, worldwide rights to develop and commercialize probody-drug conjugates for up to four...